Gaps Seen Between Hearing Loss, Receipt of Medical Evaluation, Tx

Share this content:
Gaps Seen Between Hearing Loss, Receipt of Medical Evaluation, Tx
Gaps Seen Between Hearing Loss, Receipt of Medical Evaluation, Tx

WEDNESDAY, Nov. 22, 2017 (HealthDay News) -- Many patients with self-reported hearing loss do not receive medical evaluation and recommended treatments, according to a study published online Nov. 22 in JAMA Otolaryngology-Head and Neck Surgery.

Hossein Mahboubi, M.D., M.P.H., from the University of California in Irvine, and colleagues conducted a cross-sectional analysis of responses from participants in the 2014 National Health Interview Survey who responded to the hearing module questions.

The researchers found that 16.8 percent of the 239.6 million adults indicated that their hearing was less than excellent/good, varying from "a little trouble hearing" to "deaf." In the preceding five years, about 20.6 percent of these adults had visited a physician for hearing problems. Of these, 32.6 and 27.3 percent were referred to an otolaryngologist and audiologist, respectively. Functional hearing was reported as the ability to hear whispering or normal voice, to only hear shouting, and not appreciating shouting (95.5, 3.4, and 1.1 percent, respectively). A cochlear implant was recommended for 5.3 percent of the last group, and 22.1 percent received one. Overall, 32.2 and 28.0 percent of the adults who indicated their hearing ranged from a little trouble hearing to deaf had never seen a clinician for hearing problems and had never had their hearing tested, respectively.

"Improved awareness regarding referrals to otolaryngologists and audiologists as well as auditory rehabilitative options among clinicians may improve hearing loss care," the authors write.

Abstract/Full Text

Share this content:

is free, fast, and customized just for you!

Already a member?

Sign In Now »

Drug Lookup

Browse drugs by: BrandGenericDisease

Trending Activities

All Professions


Sign up for myCME e-newsletters


More in Home

ASH: Anti-CD19 CAR T-Cell Tx Beneficial in B-Cell Lymphomas

ASH: Anti-CD19 CAR T-Cell Tx Beneficial in B-Cell ...

Second study shows benefit in relapsed or refractory B-cell lymphoma, follicular lymphoma

ASH: AAVD Beats ABVD for Advanced Hodgkin's Lymphoma

ASH: A+AVD Beats ABVD for Advanced Hodgkin's Lymphoma

Lower combined risk of progression, death, or noncomplete response with A+AVD

ASH: High-Dose Gene Transfer Beneficial in Severe Hemophilia A

ASH: High-Dose Gene Transfer Beneficial in Severe Hemophilia ...

Factor VIII gene transfer tied to sustained normalization of factor VIII activity levels

is free, fast, and customized just for you!

Already a member?

Sign In Now »